Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at reuters.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

A U.S. court ordered Guardant Health to pay $245.2 million to TwinStrand Biosciences and the University of Washington for willful infringement of DNA sequencing technology patents, covering around 90% of Guardant's revenue from infringing products until the patents expire in 2033.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

This damages ruling signals a tougher IP enforcement era for biotech startups using DNA sequencing; if you rely on proprietary sequencing tech, you must urgently review your patent exposure and licensing to avoid costly litigation.

◆ Coverage

1 source · 24 Aug 2026

◆ Related on Wire

◆ Topics

Biotechpatent-infringementdna-sequencinglegal-riskbiotech-ipcourt-judgment